Business
EGM Statement
EGM Statement.
About this update from Aura Renewable Acquisitions Plc
[{"type":"text","content":"\n Ardana PLC\n12 October 2006\n\n\n\n Ardana plc\n\n\n\n Result of EGM\n\n\n\n\nEdinburgh, UK, 12 October 2006 - Ardana plc (LSE: ARA.L) ('Ardana or the Company\n') confirms that all resolutions put to the Extraordinary General Meeting held\non 12 October 2006 were duly passed.\n\n\nThe 9,585,380 New Ordinary Shares of 1 penny each in the Company to be issued\npursuant to the Placing and Open Offer at a price of 115 pence per share are\nexpected to be admitted to the Official List and to trading on the London Stock\nExchange's main market for listed securities tomorrow, 13 October 2006.\nFollowing admission of the New Ordinary Shares, there will be in issue\n65,268,939 Ordinary Shares in the Company.\n\n\nFull details of the Placing and Open Offer are set out in the prospectus\npublished on 20 September 2006 (the 'Prospectus').\n\n\nTerms defined in the Prospectus have the same meaning in this announcement. A\ncopy of the Prospectus has been submitted to the FSA, and is available for\ninspection at the FSA's Document Viewing Facility, which is situated at:\nFinancial Service Authority, 25 The North Colonnade, Canary Wharf, London E14\n5HS.\n\n\nMonies raised by the Placing and Open Offer will be used to develop Oral GHS\n(EP01572) the Company's oral growth hormone secretagogue and also to launch and\npromote Emselex(R), a treatment for overactive bladder, for which agreement has\nbeen reached with Novartis Pharmaceuticals UK Limited to grant Ardana sole and\nexclusive rights to launch and promote the product in the UK for a ten year\nterm.\n\n\nEnquiries:\nArdana plc\n+44 (0)131 226 8558\nDr Maureen Lindsay, Chief Executive Officer\nGraham Lee, Chief Financial Officer\n\n\nPiper Jaffray Ltd.\n+44 (0)20 7743 8700\nJamie Adams\nJames Steel\n\n\nFinancial Dynamics\n+44 (0)20 7831 3113\nJulia Phillips\nJohn Gilbert\n\n\n\nAbout Ardana\n\nArdana plc is a pharmaceutical company focused on the discovery, development and\nmarketing of innovative products to improve human reproductive health, a $25.5\nbillion market.\n\n\nSince its foundation, Ardana has maintained a broad and balanced portfolio to\nmanage risk and actively pursues product and technology in-licensing and\nout-licensing to maintain a robust pipeline.\n\n\n\n • Ardana's lead products are summarised below:\n\n • Emselex(R), a treatment for overactive bladder for which ...